Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
Website:
http://www.atyrpharma.comNext earnings report:
14 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 23:41:27 GMTDividend
Analysts recommendations
Institutional Ownership
ATYR Latest News
SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company will present two posters related to its tRNA synthetase candidate ATYR0101 at the Keystone Symposia on Fibrosis: Inflammation, Drivers, and Therapeutic Resolution, which is scheduled to take place December 8 – 11, 2024, in Whistler, British Columbia, Canada. Details of the presentations appear below.
Topline data from phase 3 EFZO-FIT study, using efzofitimod for the treatment of patients with pulmonary sarcoidosis, expected Q3 of 2025. The 7 major pulmonary sarcoidosis markets are expected to reach a value of $53.3 billion by 2034. Topline data from the phase 2 EFZO-CONNECT study, using efzofitimod for the treatment of patients with scleroderma-related ILD, expected Q2 of 2025.
SAN DIEGO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in several upcoming investor conferences scheduled to take place in September 2024. Details of the conferences appear below: Conference: Wells Fargo Healthcare ConferenceDate: Thursday, September 5, 2024 Location: Everett, MAFormat: 1x1 Investor Meetings Conference: H.C.
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis enrollment completed with 268 patients; topline data from this 52-week study expected in the third quarter of 2025. Ended the second quarter 2024 with $81.4 million in cash, cash equivalents, restricted cash and investments.
What type of business is aTyr Pharma?
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
What sector is aTyr Pharma in?
aTyr Pharma is in the Healthcare sector
What industry is aTyr Pharma in?
aTyr Pharma is in the Biotechnology industry
What country is aTyr Pharma from?
aTyr Pharma is headquartered in United States
What is aTyr Pharma website?
https://www.atyrpharma.com
Is aTyr Pharma in the S&P 500?
No, aTyr Pharma is not included in the S&P 500 index
Is aTyr Pharma in the NASDAQ 100?
No, aTyr Pharma is not included in the NASDAQ 100 index
Is aTyr Pharma in the Dow Jones?
No, aTyr Pharma is not included in the Dow Jones index
When was aTyr Pharma the previous earnings report?
No data
When does aTyr Pharma earnings report?
The next expected earnings date for aTyr Pharma is 14 March 2025